Lexicon Pharmaceuticals’ (LXRX) Hold Rating Reaffirmed at Needham & Company LLC

Lexicon Pharmaceuticals (NASDAQ:LXRX)‘s stock had its “hold” rating restated by equities researchers at Needham & Company LLC in a research note issued on Monday,Benzinga reports.

LXRX has been the subject of several other reports. HC Wainwright reaffirmed a “buy” rating and issued a $6.00 price objective on shares of Lexicon Pharmaceuticals in a report on Wednesday, November 13th. Leerink Partners set a $6.00 price target on Lexicon Pharmaceuticals and gave the company an “outperform” rating in a research note on Friday, October 18th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $6.00.

Lexicon Pharmaceuticals Price Performance

Lexicon Pharmaceuticals stock opened at $0.71 on Monday. The company has a market capitalization of $175.99 million, a price-to-earnings ratio of -0.95 and a beta of 1.07. The stock’s 50 day moving average is $1.18 and its 200-day moving average is $1.56. The company has a current ratio of 7.45, a quick ratio of 7.43 and a debt-to-equity ratio of 0.56. Lexicon Pharmaceuticals has a 12 month low of $0.62 and a 12 month high of $3.73.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.01). The business had revenue of $1.75 million during the quarter, compared to the consensus estimate of $3.14 million. Lexicon Pharmaceuticals had a negative net margin of 4,109.41% and a negative return on equity of 107.38%. During the same period in the previous year, the firm posted ($0.21) EPS. Equities research analysts expect that Lexicon Pharmaceuticals will post -0.66 EPS for the current year.

Institutional Investors Weigh In On Lexicon Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Compagnie Lombard Odier SCmA raised its holdings in shares of Lexicon Pharmaceuticals by 6.4% during the 3rd quarter. Compagnie Lombard Odier SCmA now owns 100,000 shares of the biopharmaceutical company’s stock worth $157,000 after buying an additional 6,000 shares in the last quarter. Principal Financial Group Inc. grew its position in Lexicon Pharmaceuticals by 116.1% in the second quarter. Principal Financial Group Inc. now owns 22,759 shares of the biopharmaceutical company’s stock valued at $38,000 after acquiring an additional 12,225 shares during the last quarter. BNP Paribas Financial Markets raised its stake in Lexicon Pharmaceuticals by 71.2% during the third quarter. BNP Paribas Financial Markets now owns 31,853 shares of the biopharmaceutical company’s stock worth $50,000 after acquiring an additional 13,246 shares in the last quarter. Victory Capital Management Inc. lifted its holdings in shares of Lexicon Pharmaceuticals by 44.5% in the second quarter. Victory Capital Management Inc. now owns 45,341 shares of the biopharmaceutical company’s stock worth $76,000 after acquiring an additional 13,972 shares during the last quarter. Finally, The Manufacturers Life Insurance Company boosted its stake in shares of Lexicon Pharmaceuticals by 40.5% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 49,957 shares of the biopharmaceutical company’s stock valued at $84,000 after purchasing an additional 14,411 shares in the last quarter. 74.70% of the stock is currently owned by institutional investors.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.